The latest progress in the research and development of generic drugs of Futibatinib

Futibatinib (Futibatinib), as a FGFR2-targeted drug that has attracted attention in the field of precision treatment of cholangiocarcinoma in recent years, its generic drug research and development trends have also become a hot spot in the industry. Judging from overseas pharmaceutical regulatory trends, more and more countries are beginning to accelerate the review of generic drugs for new targeted drugs, especially alternatives to niche cancer mutation target drugs. Due to its oral administration, clear targeting, and limited treatment population base, forbatinib has given obvious demand for generic drugs in the global market, and the focus of research and development has gradually shifted from "accessibility" to "quality consistency" and "stable supply."

Currently publicly available overseas information shows that many countries have included forbatinib in their priority review drug lists, and manufacturers such as Laos have deployed production lines in advance. Among them, the Laos Luscius version of forbatinib generic drug with a specification of 4mg*35 tablets has been launched, with a price of about 2,500 yuan, making it one of the most popular alternatives to forbatinib. This version has attracted the attention of some patients because its ingredients and dissolution standards are highly consistent with the original research. Its launch also means that the international accessibility of forbatinib is rapidly increasing.

From the perspective of future trends, as a drug targeting FGFR2 gene fusion, the difficulties in the development of generic drugs for fobatinib are mainly focused on the selectivity control of FGFR inhibitors, trace impurity management and tablet stability.

It is worth noting that when choosing generic drugs, patients still need to pay attention to the regulations of the place of origin, manufacturing standards, batch consistency, and whether they have passed authoritative regulatory certification. As global generic drug technology matures, the supply of alternative drugs to forbatinib will continue to improve, and increased accessibility is expected to reduce long-term medication costs for patients, bringing more choices to patients with FGFR2-positive intrahepatic cholangiocarcinoma.

Reference materials:https://www.lytgobi.com/